8:45am ET
Health and Healthcare
Why Gilead Sciences Whiffed in Q1
Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.
Chris Lange
Companies
/Healthcare
Gilead Sciences Inc
$148.09
▼ $0.68 (−0.46%) today
Markets closed · 12:51am ET
GILD Coverage
Page 18 Chris Lange 12:05pm ET
Health and Healthcare
Will Gilead Sciences Earnings Get a Boost From a Collaboration?
Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since an announced collaboration with Sangamo Therapeutics.
Chris Lange 8:40am ET
Health and Healthcare
Major Biotechs Face Rising Tide of Short Interest
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
9:05am ET
Health and Healthcare
Short Sellers Back Way Off Major Biotechs
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
9:30am ET
Health and Healthcare
Major Biotechs See Rising Tide in Short Interest
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
9:45am ET
Health and Healthcare
Major Biotechs: Tough Call for Short Sellers
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
10:05am ET
Health and Healthcare
5 Top Jefferies Health Care Picks Have Big-Time Potential
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
9:15am ET
Health and Healthcare
Major Biotechs Continue to See a Rising Tide of Short Interest
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big…
10:20am ET
Health and Healthcare
Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
2:52pm ET
Health and Healthcare
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
10:20am ET
Health and Healthcare
Meet Gilead and Sangamo’s Next Big Cancer Collaboration
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
8:10am ET
Health and Healthcare
Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
9:15am ET
Health and Healthcare
Major Biotechs See Rising Tide of Short Interest
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
9:10am ET
Investing
Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More
The top analyst upgrades, downgrades and other research calls from Thursday include Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp and Zynga.
10:25am ET
Investing
Disney, Tesla, Twitter and More Earnings Coming This Week
24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.